Riga East University Hospital
- Address
- Lielvardes Street 68, LV-1006 Riga, Latvia
Eye Diseases
At Riga East University Hospital, the ophthalmology research portfolio focuses on diabetic macular edema and related chorioretinal vascular diseases, including wet age-related macular degeneration and other retinal conditions. These studies are designed to assess new treatment options, compare their effectiveness with established therapies, and support better vision outcomes for patients.
- Evaluating new therapies for diabetic macular edema and vision preservation
- Comparing treatment effectiveness in wet macular degeneration and other retinal diseases
- Studying safety and handling of eye treatments for chorioretinal vascular disease
The site is contributing to research that aims to improve visual acuity, strengthen ocular safety, and expand options for people living with chronic retinal disease.
Immune System Diseases
The endocrinology and immune system disease research at Riga East University Hospital includes studies in Graves’ disease, with a focus on finding better ways to control thyroid overactivity and maintain stable hormone levels over time. These trials are helping evaluate whether newer treatments can improve disease control and reduce the need for ongoing medication.
- Assessing new treatment approaches for Graves’ disease
- Measuring how well therapy restores and maintains normal thyroid function
- Exploring longer-term disease control in autoimmune thyroid disease
Overall, the research is centered on improving symptom management, supporting sustained euthyroidism, and offering more durable care options for patients with autoimmune thyroid conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Immunovant Sciences GmbH2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Immunovant Sciences GmbH2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Riga East University Hospital
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized Study of IMVT-1402 Versus Placebo in Adult Patients with Graves' Disease | Immunovant Sciences GmbH | Phase II | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| IMEROPRUBART | 2 | Unknown | 2025-11-21 | 2026-05-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.